Emergent Biosolutions Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Emergent Biosolutions Inc has an operating margin of -10.4%, meaning the company retains $-10 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -69.2% the prior year.
Emergent Biosolutions Inc's revenue declined 0.5% year-over-year, from $1.0B to $1.0B. This contraction results in a growth score of 27/100.
Emergent Biosolutions Inc has a moderate D/E ratio of 1.37. This balance of debt and equity financing earns a leverage score of 60/100.
With a current ratio of 3.69, Emergent Biosolutions Inc holds $3.69 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Emergent Biosolutions Inc's free cash flow margin of 3.4% results in a low score of 17/100. Capital expenditures of $22.9M absorb a large share of operating cash flow.
Emergent Biosolutions Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Emergent Biosolutions Inc generates $-0.31 in operating cash flow ($58.7M OCF vs -$190.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Emergent Biosolutions Inc earns $-1.5 in operating income for every $1 of interest expense (-$108.7M vs $71.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Emergent Biosolutions Inc (EBS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Emergent Biosolutions Inc generated $1.0B in revenue in fiscal year 2024. This represents a decrease of 0.5% from the prior year.
Emergent Biosolutions Inc's EBITDA was $100K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.0% from the prior year.
Emergent Biosolutions Inc generated $35.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 113.9% from the prior year.
Emergent Biosolutions Inc reported -$190.6M in net income in fiscal year 2024. This represents an increase of 74.9% from the prior year.
Emergent Biosolutions Inc earned $-3.60 per diluted share (EPS) in fiscal year 2024. This represents an increase of 75.8% from the prior year.
Emergent Biosolutions Inc held $99.5M in cash against $663.7M in long-term debt as of fiscal year 2024.
Emergent Biosolutions Inc had 54M shares outstanding in fiscal year 2024. This represents an increase of 4.7% from the prior year.
Emergent Biosolutions Inc's operating margin was -10.4% in fiscal year 2024, reflecting core business profitability. This is up 58.8 percentage points from the prior year.
Emergent Biosolutions Inc's net profit margin was -18.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 54.2 percentage points from the prior year.
Emergent Biosolutions Inc invested $70.7M in research and development in fiscal year 2024. This represents a decrease of 36.5% from the prior year.
Emergent Biosolutions Inc spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
Emergent Biosolutions Inc invested $22.9M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 55.6% from the prior year.
EBS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $231.1M+64.0% | $140.9M-36.6% | $222.2M+14.1% | $194.7M-23.6% | $254.7M-15.2% | $300.4M+8.6% | $276.6M+2.3% | $270.5M |
| Cost of Revenue | $85.9M+28.4% | $66.9M-24.4% | $88.5M-27.8% | $122.6M-58.6% | $296.1M+104.8% | $144.6M-21.9% | $185.1M+4.7% | $176.8M |
| Gross Profit | $145.2M+96.2% | $74.0M-44.7% | $133.7M-17.1% | $161.2M+435.8% | -$48.0M-132.5% | $147.8M+74.3% | $84.8M-2.8% | $87.2M |
| R&D Expenses | $13.5M+8.0% | $12.5M-17.2% | $15.1M+65.9% | $9.1M-72.2% | $32.7M+116.6% | $15.1M-48.6% | $29.4M+92.2% | $15.3M |
| SG&A Expenses | $38.9M-11.0% | $43.7M-16.6% | $52.4M-13.8% | $60.8M-29.2% | $85.9M+1.4% | $84.7M-5.6% | $89.7M+4.3% | $86.0M |
| Operating Income | $76.5M+4681.3% | $1.6M-96.8% | $49.9M+625.3% | -$9.5M+95.3% | -$203.5M-611.3% | $39.8M+190.9% | -$43.8M+81.9% | -$242.1M |
| Interest Expense | $15.2M+3.4% | $14.7M0.0% | $14.7M-0.7% | $14.8M-37.3% | $23.6M-2.9% | $24.3M+12.0% | $21.7M+10.2% | $19.7M |
| Income Tax | $6.4M+233.3% | -$4.8M-119.4% | $24.7M+567.6% | $3.7M-72.2% | $13.3M+329.0% | $3.1M+162.0% | -$5.0M-100.0% | -$2.5M |
| Net Income | $51.2M+526.7% | -$12.0M-117.6% | $68.0M+317.3% | -$31.3M+88.9% | -$283.1M-3245.6% | $9.0M+118.2% | -$49.5M+81.2% | -$263.4M |
| EPS (Diluted) | $0.91+513.6% | $-0.22-118.5% | $1.19+364.4% | $-0.45+91.6% | $-5.38-3264.7% | $0.17+118.9% | $-0.90+82.3% | $-5.08 |
EBS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B+3.1% | $1.4B-0.6% | $1.4B+2.6% | $1.4B-8.2% | $1.5B-16.1% | $1.8B-1.1% | $1.8B-3.7% | $1.9B |
| Current Assets | $786.9M+9.4% | $719.5M+1.8% | $706.8M+18.1% | $598.7M-8.5% | $654.5M-4.1% | $682.4M+0.4% | $679.5M-5.7% | $720.8M |
| Cash & Equivalents | $245.5M-8.2% | $267.3M+79.3% | $149.1M+49.8% | $99.5M+42.8% | $69.7M-11.2% | $78.5M-29.7% | $111.7M+27.2% | $87.8M |
| Inventory | $356.3M+5.2% | $338.6M+7.8% | $314.0M+0.7% | $311.7M-1.8% | $317.5M-4.8% | $333.4M+1.4% | $328.9M-7.1% | $354.1M |
| Accounts Receivable | $149.5M+87.3% | $79.8M-60.8% | $203.7M+31.8% | $154.5M-21.3% | $196.3M-15.9% | $233.5M+22.3% | $191.0M-11.8% | $216.5M |
| Goodwill | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $878.5M-0.3% | $880.9M+0.9% | $873.4M-3.7% | $906.9M-19.5% | $1.1B-1.1% | $1.1B-2.9% | $1.2B-1.8% | $1.2B |
| Current Liabilities | $136.5M+7.4% | $127.1M+13.6% | $111.9M-31.1% | $162.4M-73.8% | $619.7M-1.7% | $630.2M-3.2% | $651.3M-1.9% | $664.0M |
| Long-Term Debt | $663.1M-0.7% | $667.8M+0.3% | $665.7M+0.3% | $663.7M+48.5% | $447.0M+0.1% | $446.7M0.0% | $446.5M-0.4% | $448.2M |
| Total Equity | $582.5M+8.6% | $536.2M-3.0% | $552.7M+14.5% | $482.8M+25.0% | $386.3M-41.8% | $663.9M+2.2% | $649.3M-6.9% | $697.2M |
| Retained Earnings | -$105.2M+32.7% | -$156.4M-8.3% | -$144.4M+32.0% | -$212.4M+28.2% | -$295.9M-2211.7% | -$12.8M+41.3% | -$21.8M-178.7% | $27.7M |
EBS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M-102.2% | $106.4M+1050.0% | -$11.2M+86.0% | -$79.9M-268.2% | $47.5M+175.9% | -$62.6M-295.0% | $32.1M-46.5% | $60.0M |
| Capital Expenditures | $3.4M+17.2% | $2.9M-19.4% | $3.6M+111.8% | $1.7M-63.0% | $4.6M-57.4% | $10.8M-5.3% | $11.4M-9.5% | $12.6M |
| Free Cash Flow | -$5.7M-105.5% | $103.5M+799.3% | -$14.8M+81.9% | -$81.6M-290.2% | $42.9M+158.4% | -$73.4M-454.6% | $20.7M-56.3% | $47.4M |
| Investing Cash Flow | -$3.4M-119.8% | $17.2M-71.1% | $59.5M+108.0% | $28.6M+721.7% | -$4.6M+57.4% | -$10.8M+5.3% | -$11.4M+39.7% | -$18.9M |
| Financing Cash Flow | -$15.9M-148.4% | -$6.4M-1500.0% | -$400K-180.0% | $500K+101.0% | -$50.9M-225.1% | $40.7M+766.0% | $4.7M+110.9% | -$43.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $8.9M | N/A | N/A | $0 | N/A | N/A | $0 | $0 |
EBS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.8%+10.3pp | 52.5%-7.7pp | 60.2%+5.3pp | 54.9%+73.7pp | -18.9%-68.0pp | 49.2%+18.5pp | 30.7%-1.6pp | 32.2% |
| Operating Margin | 33.1%+32.0pp | 1.1%-21.3pp | 22.5%+27.3pp | -4.9%+75.0pp | -79.9%-93.2pp | 13.3%+29.1pp | -15.8%+73.7pp | -89.5% |
| Net Margin | 22.1%+30.7pp | -8.5%-39.1pp | 30.6%+46.7pp | -16.1%+95.1pp | -111.1%-114.1pp | 3.0%+20.9pp | -17.9%+79.5pp | -97.4% |
| Return on Equity | 8.8% | N/A | 12.3%-10.3pp | 22.6% | N/A | 1.4% | N/A | N/A |
| Return on Assets | 3.5%+4.4pp | -0.9%-5.6pp | 4.8%+7.0pp | -2.3%+16.4pp | -18.7%-19.2pp | 0.5%+3.2pp | -2.7%+11.2pp | -13.9% |
| Current Ratio | 5.76+0.1 | 5.66-0.7 | 6.32+2.6 | 3.69+2.6 | 1.06-0.0 | 1.08+0.0 | 1.04-0.0 | 1.09 |
| Debt-to-Equity | 1.14-0.1 | 1.25+0.0 | 1.20-0.2 | 1.37+0.2 | 1.16+0.5 | 0.67-0.0 | 0.69+0.0 | 0.64 |
| FCF Margin | -2.5%-75.9pp | 73.5%+80.1pp | -6.7%+35.3pp | -41.9%-58.7pp | 16.8%+41.3pp | -24.4%-31.9pp | 7.5%-10.0pp | 17.5% |
Similar Companies
Frequently Asked Questions
What is Emergent Biosolutions Inc's annual revenue?
Emergent Biosolutions Inc (EBS) reported $1.0B in total revenue for fiscal year 2024. This represents a -0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Emergent Biosolutions Inc's revenue growing?
Emergent Biosolutions Inc (EBS) revenue declined by 0.5% year-over-year, from $1.0B to $1.0B in fiscal year 2024.
Is Emergent Biosolutions Inc profitable?
No, Emergent Biosolutions Inc (EBS) reported a net income of -$190.6M in fiscal year 2024, with a net profit margin of -18.3%.
What is Emergent Biosolutions Inc's earnings per share (EPS)?
Emergent Biosolutions Inc (EBS) reported diluted earnings per share of $-3.60 for fiscal year 2024. This represents a 75.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Emergent Biosolutions Inc's EBITDA?
Emergent Biosolutions Inc (EBS) had EBITDA of $100K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Emergent Biosolutions Inc have?
As of fiscal year 2024, Emergent Biosolutions Inc (EBS) had $99.5M in cash and equivalents against $663.7M in long-term debt.
What is Emergent Biosolutions Inc's operating margin?
Emergent Biosolutions Inc (EBS) had an operating margin of -10.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Emergent Biosolutions Inc's net profit margin?
Emergent Biosolutions Inc (EBS) had a net profit margin of -18.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Emergent Biosolutions Inc's free cash flow?
Emergent Biosolutions Inc (EBS) generated $35.8M in free cash flow during fiscal year 2024. This represents a 113.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Emergent Biosolutions Inc's operating cash flow?
Emergent Biosolutions Inc (EBS) generated $58.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Emergent Biosolutions Inc's total assets?
Emergent Biosolutions Inc (EBS) had $1.4B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Emergent Biosolutions Inc's capital expenditures?
Emergent Biosolutions Inc (EBS) invested $22.9M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Emergent Biosolutions Inc spend on research and development?
Emergent Biosolutions Inc (EBS) invested $70.7M in research and development during fiscal year 2024.
How many shares does Emergent Biosolutions Inc have outstanding?
Emergent Biosolutions Inc (EBS) had 54M shares outstanding as of fiscal year 2024.
What is Emergent Biosolutions Inc's current ratio?
Emergent Biosolutions Inc (EBS) had a current ratio of 3.69 as of fiscal year 2024, which is generally considered healthy.
What is Emergent Biosolutions Inc's debt-to-equity ratio?
Emergent Biosolutions Inc (EBS) had a debt-to-equity ratio of 1.37 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Emergent Biosolutions Inc's return on assets (ROA)?
Emergent Biosolutions Inc (EBS) had a return on assets of -13.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Emergent Biosolutions Inc's Piotroski F-Score?
Emergent Biosolutions Inc (EBS) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Emergent Biosolutions Inc's earnings high quality?
Emergent Biosolutions Inc (EBS) has an earnings quality ratio of -0.31x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Emergent Biosolutions Inc cover its interest payments?
Emergent Biosolutions Inc (EBS) has an interest coverage ratio of -1.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Emergent Biosolutions Inc?
Emergent Biosolutions Inc (EBS) scores 41 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.